APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeted PSMA Radionuclide Drug Conjugates

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Targeted PSMA Radionuclide Drug Conjugates Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchTargeted PSMA Radionuclide Drug Conjugates Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted PSMA Radionuclide Drug Conjugates Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Targeted PSMA Radionuclide Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted PSMA Radionuclide Drug Conjugates Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted PSMA Radionuclide Drug Conjugates Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Targeted PSMA Radionuclide Drug Conjugates market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Targeted PSMA Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Targeted PSMA Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeted PSMA Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Targeted PSMA Radionuclide Drug Conjugates market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Targeted PSMA Radionuclide Drug Conjugates market include Grand Pharmaceutical, Novartis, University of California, Telix Pharmaceutical and Lantheus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Targeted PSMA Radionuclide Drug Conjugates market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeted PSMA Radionuclide Drug Conjugates and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeted PSMA Radionuclide Drug Conjugates sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Targeted PSMA Radionuclide Drug Conjugates market size, projected growth trends, production technologies, key applications, and end-use industries.

Targeted PSMA Radionuclide Drug Conjugates Segment by Company

Grand Pharmaceutical

Novartis

University of California

Telix Pharmaceutical

Lantheus

Targeted PSMA Radionuclide Drug Conjugates Segment by Type

Diagnostic

Therapeutic

Targeted PSMA Radionuclide Drug Conjugates Segment by Application

Hospital

Specialist Clinic

Other

Targeted PSMA Radionuclide Drug Conjugates Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Targeted PSMA Radionuclide Drug Conjugates status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Targeted PSMA Radionuclide Drug Conjugates market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Targeted PSMA Radionuclide Drug Conjugates significant trends, drivers, influence factors in global and regions.

6. To analyze Targeted PSMA Radionuclide Drug Conjugates competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted PSMA Radionuclide Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted PSMA Radionuclide Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted PSMA Radionuclide Drug Conjugates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Targeted PSMA Radionuclide Drug Conjugates market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted PSMA Radionuclide Drug Conjugates industry.

Chapter 3: Detailed analysis of Targeted PSMA Radionuclide Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Targeted PSMA Radionuclide Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Targeted PSMA Radionuclide Drug Conjugates in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Targeted PSMA Radionuclide Drug Conjugates Industry Trends Table 2. Targeted PSMA Radionuclide Drug Conjugates Industry Drivers Table 3. Targeted PSMA Radionuclide Drug Conjugates Industry Opportunities and Challenges Table 4. Targeted PSMA Radionuclide Drug Conjugates Industry Restraints Table 5. Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Share by Company (2021-2026) Table 7. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Company (2021-2026) Table 9. Global Targeted PSMA Radionuclide Drug Conjugates Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Targeted PSMA Radionuclide Drug Conjugates Company Ranking, (2024-2026) & (USD Million) Table 11. Global Targeted PSMA Radionuclide Drug Conjugates Key Company Manufacturing Base & Headquarters Table 12. Global Targeted PSMA Radionuclide Drug Conjugates Company, Product Type & Application Table 13. Global Targeted PSMA Radionuclide Drug Conjugates Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Targeted PSMA Radionuclide Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diagnostic Table 18. Significant Companies of Therapeutic Table 19. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Type (2021-2026) Table 23. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Type (2027-2032) Table 24. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type (2021-2026) Table 28. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Specialist Clinic Table 31. Significant Companies of Other Table 32. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Application (2021-2026) Table 36. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Application (2027-2032) Table 37. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application (2021-2026) Table 41. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application (2027-2032) Table 42. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2021-2026) & (K Units) Table 44. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Region (2021-2026) Table 45. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2027-2032) & (K Units) Table 46. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Region (2027-2032) Table 47. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Region (2021-2026) Table 50. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Region (2027-2032) Table 52. Global Targeted PSMA Radionuclide Drug Conjugates Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Targeted PSMA Radionuclide Drug Conjugates Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 57. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2026) Table 58. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 59. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2027-2032) Table 60. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Market Share by Country (2021-2026) Table 62. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Market Share by Country (2027-2032) Table 64. Grand Pharmaceutical Company Information Table 65. Grand Pharmaceutical Business Overview Table 66. Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 68. Grand Pharmaceutical Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 73. Novartis Recent Development Table 74. University of California Company Information Table 75. University of California Business Overview Table 76. University of California Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. University of California Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 78. University of California Recent Development Table 79. Telix Pharmaceutical Company Information Table 80. Telix Pharmaceutical Business Overview Table 81. Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 83. Telix Pharmaceutical Recent Development Table 84. Lantheus Company Information Table 85. Lantheus Business Overview Table 86. Lantheus Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 88. Lantheus Recent Development Table 89. Key Raw Materials Table 90. Raw Materials Key Suppliers Table 91. Targeted PSMA Radionuclide Drug Conjugates Distributors List Table 92. Targeted PSMA Radionuclide Drug Conjugates Customers List Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Targeted PSMA Radionuclide Drug Conjugates Product Image Figure 2. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 4. Global Targeted PSMA Radionuclide Drug Conjugates Sales (2021-2032) & (K Units) Figure 5. Global Targeted PSMA Radionuclide Drug Conjugates Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Targeted PSMA Radionuclide Drug Conjugates Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diagnostic Image Figure 10. Therapeutic Image Figure 11. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Type (2021-2032) Figure 14. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Specialist Clinic Image Figure 19. Other Image Figure 20. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Application (2021-2032) Figure 23. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application (2021-2032) Figure 26. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 31. North America Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 37. South America Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Targeted PSMA Radionuclide Drug Conjugates Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Targeted PSMA Radionuclide Drug Conjugates Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic
  • Therapeutic
Applications
  • Hospital
  • Specialist Clinic
  • Other
Companies covered
  • Grand Pharmaceutical
  • Novartis
  • University of California
  • Telix Pharmaceutical
  • Lantheus

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032)
  4. 1.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume (2021-2032)
  5. 1.2.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Targeted PSMA Radionuclide Drug Conjugates Market Dynamics
  1. 2.1 Targeted PSMA Radionuclide Drug Conjugates Industry Trends
  2. 2.2 Targeted PSMA Radionuclide Drug Conjugates Industry Drivers
  3. 2.3 Targeted PSMA Radionuclide Drug Conjugates Industry Opportunities and Challenges
  4. 2.4 Targeted PSMA Radionuclide Drug Conjugates Industry Restraints
3 Targeted PSMA Radionuclide Drug Conjugates Market by Company
  1. 3.1 Global Targeted PSMA Radionuclide Drug Conjugates Company Revenue Ranking in 2025
  2. 3.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Company (2021-2026)
  3. 3.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Company (2021-2026)
  4. 3.4 Global Targeted PSMA Radionuclide Drug Conjugates Average Price by Company (2021-2026)
  5. 3.5 Global Targeted PSMA Radionuclide Drug Conjugates Company Ranking (2024-2026)
  6. 3.6 Global Targeted PSMA Radionuclide Drug Conjugates Company Manufacturing Base and Headquarters
  7. 3.7 Global Targeted PSMA Radionuclide Drug Conjugates Company Product Type and Application
  8. 3.8 Global Targeted PSMA Radionuclide Drug Conjugates Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Targeted PSMA Radionuclide Drug Conjugates Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Targeted PSMA Radionuclide Drug Conjugates Market by Type
  1. 4.1 Targeted PSMA Radionuclide Drug Conjugates Type Introduction
  2. 4.1.1 Diagnostic
  3. 4.1.2 Therapeutic
  4. 4.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Type
  5. 4.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Type
  9. 4.3.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Type (2021-2032)
  11. 4.3.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type (2021-2032)
5 Targeted PSMA Radionuclide Drug Conjugates Market by Application
  1. 5.1 Targeted PSMA Radionuclide Drug Conjugates Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Specialist Clinic
  4. 5.1.3 Other
  5. 5.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Application
  6. 5.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Application
  10. 5.3.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Application (2021-2032)
  12. 5.3.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application (2021-2032)
6 Targeted PSMA Radionuclide Drug Conjugates Regional Sales and Value Analysis
  1. 6.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2021-2032)
  3. 6.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region: 2021-2026
  4. 6.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2027-2032)
  5. 6.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Region (2021-2032)
  7. 6.4.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Region: 2021-2026
  8. 6.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Region (2027-2032)
  9. 6.5 Global Targeted PSMA Radionuclide Drug Conjugates Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032)
  12. 6.6.2 North America Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032)
  15. 6.7.2 Europe Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032)
  21. 6.9.2 South America Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Country, 2025 VS 2032
7 Targeted PSMA Radionuclide Drug Conjugates Country-level Sales and Value Analysis
  1. 7.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2032)
  4. 7.3.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026)
  5. 7.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2027-2032)
  6. 7.4 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Country (2021-2032)
  7. 7.4.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Country (2021-2026)
  8. 7.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Targeted PSMA Radionuclide Drug Conjugates Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Targeted PSMA Radionuclide Drug Conjugates Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Grand Pharmaceutical
  2. 8.1.1 Grand Pharmaceutical Company Information
  3. 8.1.2 Grand Pharmaceutical Business Overview
  4. 8.1.3 Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  6. 8.1.5 Grand Pharmaceutical Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 University of California
  14. 8.3.1 University of California Company Information
  15. 8.3.2 University of California Business Overview
  16. 8.3.3 University of California Targeted PSMA Radionuclide Drug Conjugates Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 University of California Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  18. 8.3.5 University of California Recent Developments
  19. 8.4 Telix Pharmaceutical
  20. 8.4.1 Telix Pharmaceutical Company Information
  21. 8.4.2 Telix Pharmaceutical Business Overview
  22. 8.4.3 Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  24. 8.4.5 Telix Pharmaceutical Recent Developments
  25. 8.5 Lantheus
  26. 8.5.1 Lantheus Company Information
  27. 8.5.2 Lantheus Business Overview
  28. 8.5.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  30. 8.5.5 Lantheus Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Targeted PSMA Radionuclide Drug Conjugates Value Chain Analysis
  2. 9.1.1 Targeted PSMA Radionuclide Drug Conjugates Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Targeted PSMA Radionuclide Drug Conjugates Sales Mode & Process
  6. 9.2 Targeted PSMA Radionuclide Drug Conjugates Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Targeted PSMA Radionuclide Drug Conjugates Distributors
  9. 9.2.3 Targeted PSMA Radionuclide Drug Conjugates Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst